Bristol-Myers Squibb Company (BRM.DE)
XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
As of 09:31AM CEST. Market open.
| Previous Close | 39.29 |
| Open | 39.62 |
| Bid | 39.12 x 37000 |
| Ask | 39.24 x 43000 |
| Day's Range | 39.17 - 39.62 |
| 52 Week Range | 36.90 - 59.70 |
| Volume | |
| Avg. Volume | 5,003 |
| Market Cap | 79.412B |
| Beta (5Y Monthly) | 0.43 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.23 (5.69%) |
| Ex-Dividend Date | Jul 05, 2024 |
| 1y Target Est | N/A |
- Business Wire
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
PRINCETON, N.J., June 21, 2024--Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with...
- Business Wire
European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab
PRINCETON, N.J., June 21, 2024--European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab
- Business Wire
Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024
PRINCETON, N.J., June 20, 2024--Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024
© 2024 Yahoo. All rights reserved.